• China’s NMPA granted NDA clearance for CanSino’s adsorbed tetanus vaccine.
• Product targets non-neonatal tetanus prevention, expanding the company’s adult vaccine portfolio.
• Exclusive commercialization rights in Greater China were granted to Grand Life Sciences Group.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cansino Biologics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260820-12292672), on August 20, 2026, and is solely responsible for the information contained therein.